Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers
- PMID: 2465100
- DOI: 10.1161/01.cir.79.3.666
Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers
Abstract
After addition of a low concentration of thrombin to normal plasma, a progressive and significant increase in crosslinked fibrin polymers was found by sodium dodecyl sulfate agarose gel electrophoresis, reaching 27% of total fibrinogen and fibrin before gel formation. As measured by enzyme-linked immunosorbent assay with a monoclonal antibody specific for an epitope near the gamma gamma crosslink site, increased immunoreactivity of plasma did not occur after adding thrombin despite formation of crosslinked fibrin polymers, which indicates that the antibody does not recognize the epitope in the polymers. Addition of tissue-type plasminogen activator (t-PA) to plasma resulted in a more rapid degradation of fibrin polymers than of fibrinogen, indicating that the fibrin specificity of t-PA is retained with soluble fibrin. Coincident with degradation of plasma crosslinked fibrin polymers, plasma DD immunoreactivity increased 70-fold from 50.3 +/- 4.5 (mean +/- SD) to 3,560 +/- 1,235 ng/ml. The presence of increased crosslinked fibrin polymers produced by adding thrombin to plasma significantly increased maximum immunoreactivity after t-PA-induced degradation to 18,500 +/- 11,780 ng/ml. The increase in DD immunoreactivity was dependent on t-PA concentration; no elevation occurred below 0.01 micrograms/ml, and maximal increases occurred above 100 micrograms/ml. Analysis of gel electrophoretic patterns of thrombin and t-PA-treated plasma samples suggests that the DD reactivity of t-PA-treated plasma is mainly due to degradation of soluble crosslinked fibrin polymers. Our findings indicate that plasmic degradation of soluble fibrin polymers in plasma may be an important source of fragment DD during thrombolytic therapy.
Similar articles
-
Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders.Blood. 1992 Aug 1;80(3):709-17. Blood. 1992. PMID: 1386260
-
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.Circulation. 1990 Oct;82(4):1159-68. doi: 10.1161/01.cir.82.4.1159. Circulation. 1990. PMID: 2119264
-
Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.Blood. 1985 Mar;65(3):589-97. Blood. 1985. PMID: 3971042
-
Fibrin-specific thrombolytic agents.Klin Wochenschr. 1988;66 Suppl 12:15-23. Klin Wochenschr. 1988. PMID: 3126344 Review.
-
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202. J Cell Biochem. 1987. PMID: 3553213 Review.
Cited by
-
Thrombin antithrombin complex and IL-18 serum levels in stroke patients.Neurol Int. 2010 Jun 21;2(1):e1. doi: 10.4081/ni.2010.e1. Neurol Int. 2010. PMID: 21577333 Free PMC article.
-
Clarification of fibrin generation and degradation reaction processes of clot-fibrinolysis waveform in hemorrhagic disorders.PLoS One. 2025 Aug 18;20(8):e0320111. doi: 10.1371/journal.pone.0320111. eCollection 2025. PLoS One. 2025. PMID: 40824945 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials